Drug Watch

Latest News

FDA Accepts sNDA for Arcutis' Roflumilast Cream 0.15% for Atopic Dermatitis, Sets July 2024 PDUFA Date
FDA Accepts sNDA for Arcutis' Roflumilast Cream 0.15% for Atopic Dermatitis, Sets July 2024 PDUFA Date

November 29th 2023

The sNDA is supported by positive data from the phase 3 INTEGUMENT-1 and INTEGUMENT-2 trials.

FDA Grants Priority Review of Abeona’s Pz-cel BLA for Recessive DEB
FDA Grants Priority Review of Abeona’s Pz-cel BLA for Recessive DEB

November 28th 2023

CVS Removes Biosimilars From Drug List
CVS Removes Biosimilars From Drug List

November 22nd 2023

KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study
KT-474 Demonstrates Efficacy and Promise in Atopic Dermatitis and Hidradenitis Suppurativa Study

November 20th 2023

FDA Grants Breakthrough Therapy Designation to QTORIN Rapamycin for Microcystic Lymphatic Malformations
FDA Grants Breakthrough Therapy Designation to QTORIN Rapamycin for Microcystic Lymphatic Malformations

November 16th 2023

© 2023 MJH Life Sciences

All rights reserved.